

4121-135

**Section I (Amendments to the Specification)**

At pages 5 and 6, replace the paragraph bridging pages 5 and 6, beginning "Figure 1 shows the pKID16-30 expression..." and ending "according to the invention." with the following new replacement paragraph:

Figure 1 shows the pKID16-30 expression vector (SEQ ID NO:1) according to the invention. It codes for two single-chain F<sub>V</sub> antibody constructs, one of which (SEQ ID NO: 2) having the V<sub>H</sub> domain of an anti-CD16 antibody and the V<sub>L</sub> domain of an anti-CD30 antibody and the other (SEQ ID NO:3) having the V<sub>H</sub> domain of an anti-CD30 antibody and the V<sub>L</sub> domain of an anti-CD16 antibody. Having expressed the single-chain F<sub>V</sub> antibody constructs, they are placed together so as to obtain the F<sub>V</sub> antibody construct according to the invention.

At page 7 of the application, replace the paragraph beginning "The cDNA of the ..." and ending with "in the pHOG21 vector." with the following new replacement paragraph:

The cDNA of the V<sub>H</sub> and V<sub>L</sub> domains of an anti-CD16 antibody mAb A9 was subjected to PCR. The following primers were used for this purpose:

VH5', 5-CAGCCGGCCATGGCGCAGGTC(G)CAGCTGCAGC(G)AG-3 (NcoI) (SEQ ID NO: 4);

VH3', 5-CCAGGGGCCAGTGGATAGACAAGCTTGGGTGTTGTTTT-3 (HindIII) (SEQ ID NO: 5);

VL5', 5-AGAGACGCGTACAGGCTGTTGTGACTCAGG-3 (MluI) (SEQ ID NO: 6);

VL3', 5-GACTandAGACTTGGGCTGGCC-3 (NotI) (SEQ ID NO: 7)

PCR was carried out as follows: one cycle; 5 min. and 94° C, 3 min. at 58° C, and 2 min. at 72° C, followed by 30 cycles; 80 sec. and 94° C, 80 sec. at 58° C, and 2 min. at 72° C and/or the latter 10 min. in the last cycle. The PCR products were gel-purified and inserted in the pCR-Script SK(+) vector (Stratagene company) for sequencing. For the purpose of expression, the V<sub>H</sub> domain was inserted via NcoI/HindIII and the V<sub>L</sub> domain was inserted via MluI/NotI in the pHOG21 vector.

4121-135

At pages 7 and 8 of the application, replace the paragraph bridging pages 7 and 8, beginning "The V<sub>H</sub> and VL domains of an anti-CD30-scF<sub>v</sub> fragment ..." and ending "V<sub>H</sub> 30-V<sub>L</sub> 16." with the following new replacement paragraph:

The V<sub>H</sub> and VL domains of an anti-CD30-scF<sub>v</sub> fragment were subjected to PCR. The following primers were used for this:

5-ATGACCATGATTACGCCAAGC-3 (SEQ ID NO: 8)

5-AGACAAAGCTTGGGTGTTGTTTGTGCTGAGGAGACGG-3 (HindIII) (SEQ ID NO: 9)

5-GGCGGATATCGAGCTCACTCAGTCTCC-3 (EcoRV) (SEQ ID NO: 10)

5-TATAGCGGCGCAGCATCAGCCCGTTTGATTTC-3 (NotI) (SEQ ID NO: 11)

The V<sub>H</sub> and VL domains of the anti-CD30-scF<sub>v</sub> fragment or the anti-CD16-scF<sub>v</sub> fragment were inserted in the expression vector pKID so as to obtain the pKID 16-30 expression vector according to the invention. It codes for the single-chain F<sub>v</sub> antibody constructs V<sub>H</sub>, 16-V<sub>L</sub> 30 and V<sub>H</sub> 30-V<sub>L</sub> 16.